Department of Pediatrics, Division of Critical Care Medicine, Penn State Hershey Children's Hospital, Pennsylvania State University College of Medicine , Hershey, PA , USA.
Pharmacy Administration and Education Department, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine , Hershey, PA , USA.
Front Pediatr. 2014 Jun 12;2:59. doi: 10.3389/fped.2014.00059. eCollection 2014.
Aminophylline, an established bronchodilator, is also purported to be an effective diuretic and anti-inflammatory agent. However, the data to support these contentions are scant. We conducted a prospective, open-label, single arm, single center study to assess the hypothesis that aminophylline increases urine output and decreases inflammation in critically ill children.
Children less than 18 years of age admitted to the pediatric intensive care unit who were prescribed aminophylline over a 24-h period were eligible for study. The use and dosing of aminophylline was independent of the study and was at the discretion of the clinical team. Data analyzed consisted of demographics, diagnoses, medications, and markers of pulmonary function, renal function, and inflammation. Data were collected at baseline and at 24-h after aminophylline initiation with primary outcomes of change in urine output and inflammatory cytokine concentrations.
Thirty-five patients were studied. Urine output increased significantly with aminophylline use [median increase 0.5 mL/kg/h (IQR: -0.3, 1.3), p = 0.05] while blood urea nitrogen and creatinine concentrations remained unchanged. Among patients with elevated C-reactive protein concentrations, levels of both interleukin-6 (IL-6) and IL-10 decreased at 24 h of aminophylline therapy. There were no significant differences in pulmonary compliance or resistance among patients invasively ventilated at both time points. Side effects of aminophylline were detected in 7 of 35 patients.
Although no definitive conclusions can be drawn from this study, aminophylline may be a useful diuretic and effective anti-inflammatory medication in critically ill children. Given the incidence of side effects, the small sample size and the uncontrolled study design, further study is needed to inform the appropriate use of aminophylline in these children.
氨茶碱是一种已被证实的支气管扩张剂,也被认为是一种有效的利尿剂和抗炎药。然而,支持这些说法的数据很少。我们进行了一项前瞻性、开放标签、单臂、单中心研究,以评估氨茶碱增加尿量和减少危重病儿童炎症的假设。
在 24 小时内接受氨茶碱治疗的年龄小于 18 岁的儿科重症监护病房患儿符合研究条件。氨茶碱的使用和剂量与研究无关,由临床团队决定。分析的数据包括人口统计学、诊断、药物以及肺功能、肾功能和炎症标志物。数据在氨茶碱开始使用前和使用 24 小时后收集,主要结局为尿量和炎症细胞因子浓度的变化。
研究了 35 例患者。氨茶碱使用后尿量显著增加[中位数增加 0.5 mL/kg/h(IQR:-0.3,1.3),p=0.05],而血尿素氮和肌酐浓度保持不变。在 C 反应蛋白浓度升高的患者中,IL-6 和 IL-10 的水平在氨茶碱治疗 24 小时后均降低。在两个时间点进行有创通气的患者中,肺顺应性或阻力均无显著差异。在 35 例患者中,有 7 例出现氨茶碱的副作用。
尽管不能从这项研究中得出明确的结论,但氨茶碱可能是危重病儿童有用的利尿剂和有效的抗炎药物。鉴于副作用的发生率、样本量小和非对照研究设计,需要进一步研究以告知在这些儿童中适当使用氨茶碱。